Cabozantinib: A MET, RET, and VEGFR2 tyrosine kinase inhibitor

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 207-214

  Grülich, Carsten ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; PLACEBO; PROTEIN RET; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2; ANILIDE; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RET PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ARTICLE; CANCER FATIGUE; CANCER INHIBITION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; SURVIVAL RATE; THYROID MEDULLARY CARCINOMA; ANIMAL; DRUG ANTAGONISM; NEOPLASM; REVIEW;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84906924507     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_12     Document Type: Article

References (19)

1. Bean J et al (2007) MET amplification occurs with or without T790 M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52): 20932-20937.
2. Bussolino F et al (1992) Hepatocyte growth-factor is a potent angiogenic factor which stimulates endothelial-cell motility and growth. J Cell Biol 119(3): 629-641.
3. Direnzo MF et al (1995) Overexpression and amplification of the Met/Hgf receptor gene during the progression of colorectal-cancer. Clin Cancer Res 1(2): 147-154.
4. Houldsworth J et al (1990) Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50(19): 6417-6422.
5. Kurzrock R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29(19): 2660-2666.
6. Matsumoto K, Nakamura T (2001) Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59(6): 2023-2038.
7. Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276(5309): 60-66.
8. Mizuno S, Matsumoto K, Nakamura T (2001) Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59(4): 1304-1314.
9. Nakagawa T et al (2012) Combined therapy with mutant-selective EGFR inhibitor and met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11(10): 2149-2157.
10. Schmidt L et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1): 68-73.
11. Schoffski P et al (2012) An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30(15).
12. Sennino B et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2(3): 270-287.
13. Sirotnak FM et al (2004) Microarray analysis of progression to reduced prostate cancer androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog 41(3): 150-163.
14. Smith DC et al (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4): 412-419.
15. Soman NR et al (1991) The Tpr-Met oncogenic rearrangement is present and expressed in human gastric-carcinoma and precursor lesions. Proc Natl Acad Sci USA 88(11): 4892-4896.
16. Takayama H et al (1996) Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc Natl Acad Sci USA 93(12): 5866-5871.
17. Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2(4): 289-300.
18. Verras M et al (2007) The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67(3): 967-975.
19. Yakes FM et al (2011) Cabozantinib (XL184), a Novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12): 2298-2308.